N-ethyl-N-phenylbenzenesulfonamide | 54437-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-ethyl-N-phenylbenzenesulfonamide
• CAS: 54437-69-3
• 化学式: C₁₄H₁₅NO₂S
• mdl: MFCD00590965
• 分子量: 261.345
• InChiKey: IHKIASZHUKYNEA-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38 °C
• 沸点：
  392.9±25.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-ethyl-N-phenylbenzenesulfonamide 在 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以86%的产率得到N-乙基苯胺
  参考文献：
  名称：

  Deprotection of sulfonamides using iodotrimethylsilane

  摘要：

  The deprotection of sulfonamides is achieved under neutral conditions by reaction with iodotrimethylsilane in acetonitrile at reflux. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02646-x
• 作为产物：
  描述：

  1-(苯磺酰)-1H-苯并三唑 、 N-乙基苯胺 在 N-甲基咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 72.0h， 以78%的产率得到N-ethyl-N-phenylbenzenesulfonamide
  参考文献：
  名称：

  1-Phenylsulfonylbenzotriazole: A Novel and Convenient Reagent for the Preparation of Benzenesulfonamides and Aryl Benzenesulfonates

  摘要：

  Readily available 1-phenylsulfonylbenzotriazole smoothly converts various aliphatic and aromatic amines and phenols into the corresponding benzenesulfonamides and benzenesulfonates in good yields.

  DOI：

  10.1080/00397919408013820

文献信息

• Nanosized CdS as a Reusable Photocatalyst: The Study of Different Reaction Pathways between Tertiary Amines and Aryl Sulfonyl Chlorides through Visible-Light-Induced N-Dealkylation and C–H Activation Processes
  作者：Somayeh Firoozi、Mona Hosseini-Sarvari

  DOI：10.1021/acs.joc.0c02263

  日期：2021.2.5

  It has been found that the final products of the reaction of sulfonyl chlorides and tertiary amines in the presence of cadmium sulfide nanoparticles under visible light irradiation are highly dependent on the applied reaction conditions. Interestingly, with the change of a reaction condition, different pathways were conducted (visible-light-induced N-dealkylation or sp3 and sp2 C–H activation) that

  已经发现，在可见光辐射下，在硫化镉纳米颗粒存在下，磺酰氯和叔胺反应的最终产物高度依赖于所应用的反应条件。有趣的是，随着反应条件的改变，进行了不同的途径（可见光诱导的N-脱烷基或sp 3和sp 2C–H活化）导致产生不同的产物，例如仲胺和各种磺酰基化合物。值得注意的是，所有这些反应都是在可见光辐射下和在没有良性溶剂的情况下在无溶剂或无溶剂条件下的空气气氛下进行的。在这项研究过程中，CdS纳米颗粒作为可负担的，多相的和可回收的光催化剂被设计，成功合成并充分表征并应用于这些方案。在这些研究中，由叔胺氧化产生的中间体在光致电子转移（PET）过程中被捕获。使用可见光辐照作为可再生能源的同时，反应可在各种底物上有效地进行，从而在相对短的时间内以良好至极好的收率得到相应的产物。这些过程中的大多数都是新颖​​的，或者在成本效益，安全性和简化性方面优于已发布的报告。
• PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES
  申请人：Pfizer Inc.

  公开号：US20150329542A1

  公开（公告）日：2015-11-19

  A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A′ are independently C or N, where C may be unsubstituted or substituted by halo or C 1 -C 6 alkyl; R and R 0 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 alkyl), phenyl(C 1 -C 6 alkyl), and —(CH 2 ) n —W, where W is C 3 -C 8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N, S and/or O atoms, —SO 2 —R′, —NHSO 2 —R′, —NR″SO 2 —R′ and SR′, where R′ and R″ are independently C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R 0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, etc., or (b) —(CH 2 ) n —W, where W is C 3 -C 8 cycloalkyl, phenyl, etc.; R 1 is H, halo or cyano; R 2 and R 2′ are independently H, C 1 -C 6 alkyl, cyano, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, or C 3 -C 8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, —CO—, —CONH—, —SO 2 —, —SONH—, or —(CH 2 ) m —; R 3 is H, C 1 -C 4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent —Y—R 4 and/or 1-4 substituents each independently selected from R 5 ; with the proviso that when X is —CO— or —SO 2 —, R 3 is not H; Y is a bond, —(CH 2 ) m — or —O—; R 4 is (a) H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, halo, oxo, —OR 6 , —NR 7 R 8 , —SR 6 , —SOR 9 , —SO 2 R 9 , —COR 6 , —OCOR 6 , —OCOR 6 , —NR 6 COR 6 , —CONR 7 R 8 , etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, halo, cyano, —OR 6 , —NR 7 R 8 , etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R 6 is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; R 7 and R 8 are each independently H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C 1 -C 6 alkyl is optionally substituted by C 3 -C 8 cycloalkyl, halo, etc., and said heterocyclic ring being optionally substituted by one or more C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl groups; R 9 is C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

  具有以下结构的化合物： 或其药学上可接受的盐，或所述化合物或药学上可接受的盐的药学上可接受的溶剂，其中A和A′独立地为C或N，其中C可以是未取代的或由卤素或C 1 -C 6 烷基取代的；R和R 0 独立地选自H、C 1 -C 6 烷基、羟基(C 1 -C 6 烷基)、苯基(C 1 -C 6 烷基)和—(CH 2 ) n —W的群，其中W为C 3 -C 8 环烷基、苯基、萘基、含有1-3个N、S和/或O原子的5-或6元杂环芳基或杂环烷基，—SO 2 —R′、—NHSO 2 —R′、—NR″SO 2 —R′和SR′，其中R′和R″独立地为C 1 -C 6 烷基或C 3 -C 8 环烷基等；其中所述的每个烷基、环烷基、杂环、苯基、萘基或杂芳基可以是未取代的或由苯基、杂芳基等取代的；或者，R和R 0 以及它们结合的N原子共同形成一个可以是未取代的或由(a)卤素、羟基、杂芳基、C 1 -C 6 烷基、C 1 -C 6 烷氧基等取代的单环或双环杂环环，或(b) —(CH 2 ) n —W，其中W为C 3 -C 8 环烷基、苯基等；R 1 为H、卤素或氰基；R 2 和R 2′ 独立地为H、C 1 -C 6 烷基、氰基、C 1 -C 6 烷氧基、C 1 -C 6 烷硫基或C 3 -C 8 环烷基，其中烷基、烷氧基或环烷基可以选择性地由一个或多个氟原子取代；X为键，—CO—、—CONH—、—SO 2 —、—SONH—或—(CH 2) m —；R 3 为H、C 1 -C 4 烷基、苯基、萘基、含有1-3个N原子的5-或6元杂环芳基或杂环，一种5元杂环芳基或杂环等，或(c) 2个O或S原子和0-2个N原子；其中所述的每个苯基、萘基、杂芳基或杂环可以选择性地由烷基、1个取代基—Y—R 4 和/或1-4个独立选择自R 5 的取代基取代；但是当X为—CO—或—SO 2 —时，R 3 不是H；Y为键，—(CH 2) m —或—O—；R 4 为(a) H、C 1 -C 6 烷基、C 3 -C 8 环烷基、卤素、氧代、—OR 6 、—NR 7 R 8 、—SR 6 、—SOR 9 、—SO 2 R 9 、—COR 6 、—OCOR 6 、—OCOR 6 、—NR 6 COR 6 、—CONR 7 R 8 等；(b)苯基或萘基，所述的苯基和萘基可以选择性地由1-5个取代基选自C 1 -C 6 烷基、C 3 -C 8 环烷基、卤素、氰基、—OR 6 、—NR 7 R 8 等取代；或(c) 3到8元饱和或部分不饱和的单环杂芳基等；R 6 为H、C 1 -C 6 烷基或C 3 -C 8 环烷基等；R 7 和R 8 独立地为H、C 1 -C 6 烷基或C 3 -C 8 环烷基，或者与它们连接的氮原子共同形成含有1-2个氮原子或1个氮原子和1个氧原子的4、5或6元饱和杂环环，所述的C 1 -C 6 烷基可以选择性地由C 3 -C 8 环烷基、卤素等取代，所述的杂环环可以选择性地由一个或多个C 1 -C 6 烷基或C 3 -C 8 环烷基基团取代；R 9 为C 1 -C 6 烷基或C 3 -C 8 环烷基；m和n独立地为0、1、2或3。该发明还涉及这些化合物的药学上可接受的盐和其药学上可接受的溶剂；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是哮喘和慢性阻塞性肺病中的用途。
• Pyrazolopyridines and pyrazolopyrimidines
  申请人：Pfizer Inc.

  公开号：US10022376B2

  公开（公告）日：2018-07-17

  A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A′ are C or N, where C may be substituted by halo or C1-C6 alkyl; R and R0 are selected from the group consisting of H, C1-C6 alkyl, —(CH2)n—W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, —NR″SO2—R′, etc., where R′ and R″ are C1-C6 alkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Ro and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; R1 is H, halo or cyano; R2 and R2′ are H, C1-C6 alkyl, etc.; X is a bond, etc.; R3 is H, C1-C4 alkyl, etc.; Y is a bond, —(CH2)m—, etc. The invention also relates to compositions and uses in the treatment of various diseases.

  具有以下结构的化合物： 或其药学上可接受的盐或溶液，其中A和A′是C或N，其中C可被卤素或C1-C6烷基取代；R和R0选自由H、C1-C6烷基、-(CH2)n-W等组成的组，其中W是含有N、S和/或O原子的5或6元杂芳基或杂环基、-NR″SO2-R′等、其中R′和R″是C1-C6烷基等；其中每个烷基等可被取代；或者，R和Ro及其所键合的N原子一起形成单环或双环杂环等；R1是H、卤代或氰基；R2和R2′是H、C1-C6烷基等；X是键等；R3是H、C1-C4烷基等；Y是键、-(CH2)m-等。本发明还涉及治疗各种疾病的组合物和用途。
• Total removal of an unruptured orbital hydatid cyst
  作者：Cevdet Gökçek、Nuray Bayar、Zeki Buharal

  DOI：10.1016/s0008-4182(01)80045-4

  日期：2001.6
• Katritzky, Alan R.; Liso, Gaietano; Lunt, Edward, Journal of the Chemical Society. Perkin transactions I, 1980, p. 849 - 851
  作者：Katritzky, Alan R.、Liso, Gaietano、Lunt, Edward、Patel, Ranjan C.、Thind, Sukhpal S.、Zia, Abid

  DOI：——

  日期：——